Canntab Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CTABF research report →
Price Chart
About the company
Canntab Therapeutics Limited is a Canadian phytopharmaceutical firm dedicated to pioneering the research and development of sophisticated, pharmaceutical-grade cannabinoid preparations. The company manufactures various oral cannabis medications, including extended-release cannabinoid pills and pellets, rapidly acting cannabidiol formulations, multi-layered modified-release options, quick-dissolving flash-melt products, and dual-layer cannabinoid tablets. These offerings target a broad spectrum of health issues, such as sleep disturbances, post-traumatic stress disorder, social anxiety, various addictions, arthritis, chronic pain, appetite loss and pain linked to cancer therapies, and as an aid in managing dependency on opioids and other painkillers.
- CEO
- Richard C. Goldstein
- IPO
- 2017
- HQ
- Markham, ON, CA
Get TickerSpark's AI analysis on CTABF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.89K
- P/E
- -0.05
- PEG
- -0.00
- P/S
- 0.66
- P/B
- -0.61
- EV/EBITDA
- -0.46
- Div Yield
- 0.00%
- Gross Margin
- 23.68%
- Op Margin
- -1570.07%
- Net Margin
- -1257.49%
- ROE
- -376.90%
- ROIC
- -222.05%
Latest fiscal year · YoY change
- Revenue
- $293.36K+0.0%
- Gross Profit
- $-939,011-256.6%
- Op Income
- $-4,164,020
- Net Income
- $-3,689,186+16.5%
- EPS
- $-0.10+24.8%
- OCF Growth
- +0.1%
- FCF Growth
- +8.2%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.42
- RSI (14)
- 24
- Avg Volume
- 1.03K
No earnings-call transcripts are available for CTABF yet.
- Free Float
- 99.4%
- Shares Outstanding
- 38.91M
- Float Shares
- 38.68M
Our CTABF coverage
Recent articles, reports, and earnings notes.
No research on CTABF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CTABF report →CSE Bulletin: Delist - Canntab Therapeutics Limited (PILL)
newsfilecorp.com · Jun 14
Canntab Therapeutics Limited Provides Update on Application for Management Cease Trade Order
newsfilecorp.com · Sep 18
Canntab Therapeutics seeks to move manufacturing process as Markham lease expires
proactiveinvestors.com · Nov 22
Canntab Therapeutics provides update on recent product delivery of its cannabinoid solutions to the Nova Scotia Liquor Corporation
proactiveinvestors.com · Aug 22
Canntab Therapeutics appoints Hamish Sutherland as strategic business consultant
proactiveinvestors.com · Apr 13
Canntab Therapeutics inks affiliate deal with independent pharmacy owners in Ontario
proactiveinvestors.com · Mar 23
Canntab Therapeutics closes non-brokered private placement of secured convertible debentures for gross proceeds of $1,312,000
proactiveinvestors.com · Feb 2
Levitee Labs Teams Up With Canntab Therapeutics, Offer Cannabinoid Products As Alternatives To Opioids
benzinga.com · Jan 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.